$BBIO
BridgeBio Pharma, Inc.

2023 Q4 Form 10-Q Financial Statement

#000095017023058255 Filed on November 02, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $1.745M $4.091M
YoY Change -6.68% 1110.36%
Cost Of Revenue $598.0K $598.0K
YoY Change -7.57% -19.08%
Gross Profit $1.147M $3.493M
YoY Change -6.21% -971.07%
Gross Profit Margin 65.73% 85.38%
Selling, General & Admin $47.58M $35.78M
YoY Change 49.34% 14.71%
% of Gross Profit 4148.47% 1024.25%
Research & Development $130.8M $125.1M
YoY Change 43.92% 35.27%
% of Gross Profit 11405.75% 3582.48%
Depreciation & Amortization $1.584M $1.640M
YoY Change -4.58% -0.3%
% of Gross Profit 138.1% 46.95%
Operating Expenses $178.4M $160.9M
YoY Change 45.33% 30.08%
Operating Profit -$177.3M -$157.7M
YoY Change 45.84% 22.13%
Interest Expense -$14.69M $20.31M
YoY Change -7.6% 2.43%
% of Operating Profit
Other Income/Expense, Net $21.78M -$21.80M
YoY Change 377.59% 96.77%
Pretax Income -$170.3M -$179.5M
YoY Change 21.17% 28.03%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$168.1M -$179.5M
YoY Change 22.21% 28.03%
Net Earnings / Revenue -9635.99% -4387.39%
Basic Earnings Per Share -$1.08
Diluted Earnings Per Share -$0.96 -$1.08
COMMON SHARES
Basic Shares Outstanding 174.0M 162.5M
Diluted Shares Outstanding 163.3M

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $375.9M $543.3M
YoY Change -20.34% -2.69%
Cash & Equivalents $375.9M $505.2M
Short-Term Investments $58.95M $38.10M
Other Short-Term Assets $42.71M $44.40M
YoY Change -44.48% -11.63%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $477.6M $587.7M
YoY Change -12.98% -8.49%
LONG-TERM ASSETS
Property, Plant & Equipment $11.82M $12.41M
YoY Change -18.9% -20.44%
Goodwill
YoY Change
Intangibles $26.32M $26.92M
YoY Change -8.33% -8.16%
Long-Term Investments $58.95M
YoY Change
Other Assets $22.63M $18.68M
YoY Change 11.87% -37.48%
Total Long-Term Assets $68.79M $67.34M
YoY Change -7.27% -22.17%
TOTAL ASSETS
Total Short-Term Assets $477.6M $587.7M
Total Long-Term Assets $68.79M $67.34M
Total Assets $546.4M $655.0M
YoY Change -12.3% -10.12%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $10.66M $4.472M
YoY Change -7.81% -55.98%
Accrued Expenses $129.1M $95.00M
YoY Change 26.89% -9.52%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $143.8M $106.1M
YoY Change 18.46% -11.01%
LONG-TERM LIABILITIES
Long-Term Debt $446.4M $441.7M
YoY Change 3.59% -74.0%
Other Long-Term Liabilities $9.361M $11.79M
YoY Change -64.87% -58.25%
Total Long-Term Liabilities $455.8M $453.5M
YoY Change -0.4% 1506.7%
TOTAL LIABILITIES
Total Short-Term Liabilities $143.8M $106.1M
Total Long-Term Liabilities $455.8M $453.5M
Total Liabilities $1.889B $1.849B
YoY Change 1.12% -0.56%
SHAREHOLDERS EQUITY
Retained Earnings -$2.561B -$2.392B
YoY Change 33.49% 34.36%
Common Stock $1.481B $1.460B
YoY Change 57.77% 59.11%
Preferred Stock
YoY Change
Treasury Stock (at cost) $275.0M $275.0M
YoY Change 0.0% 0.0%
Treasury Stock Shares
Shareholders Equity -$1.354B -$1.208B
YoY Change
Total Liabilities & Shareholders Equity $546.4M $655.0M
YoY Change -12.3% -10.12%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$168.1M -$179.5M
YoY Change 22.21% 28.03%
Depreciation, Depletion And Amortization $1.584M $1.640M
YoY Change -4.58% -0.3%
Cash From Operating Activities -$124.8M -$145.2M
YoY Change 33.87% 7.44%
INVESTING ACTIVITIES
Capital Expenditures $436.0K $430.0K
YoY Change -45.57% -41.97%
Acquisitions
YoY Change
Other Investing Activities $369.0K $38.11M
YoY Change -98.03% -73.92%
Cash From Investing Activities -$67.00K $37.68M
YoY Change -100.37% -74.34%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -4.525M 307.0M
YoY Change -170.96% 21148.44%
NET CHANGE
Cash From Operating Activities -124.8M -145.2M
Cash From Investing Activities -67.00K 37.68M
Cash From Financing Activities -4.525M 307.0M
Net Change In Cash -129.4M 199.5M
YoY Change 87.82% 1418.38%
FREE CASH FLOW
Cash From Operating Activities -$124.8M -$145.2M
Capital Expenditures $436.0K $430.0K
Free Cash Flow -$125.3M -$145.6M
YoY Change 33.19% 7.17%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Central Index Key
EntityCentralIndexKey
0001743881
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Restricted Cash Noncurrent Asset Statement Of Financial Position Extensible List
RestrictedCashNoncurrentAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent
CY2023Q3 us-gaap Restricted Cash Noncurrent Asset Statement Of Financial Position Extensible List
RestrictedCashNoncurrentAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38959
dei Entity Registrant Name
EntityRegistrantName
BridgeBio Pharma, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
84-1850815
dei Entity Address Address Line1
EntityAddressAddressLine1
3160 Porter Drive
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 250
dei Entity Address City Or Town
EntityAddressCityOrTown
Palo Alto
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94304
dei City Area Code
CityAreaCode
(650)
dei Local Phone Number
LocalPhoneNumber
391-9740
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
BBIO
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
173967052
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
505213000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
376689000
CY2023Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
0
CY2022Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
51580000
CY2023Q3 us-gaap Equity Securities Fv Ni
EquitySecuritiesFvNi
38052000
CY2022Q4 us-gaap Equity Securities Fv Ni
EquitySecuritiesFvNi
43653000
CY2023Q3 us-gaap Receivables Long Term Contracts Or Programs
ReceivablesLongTermContractsOrPrograms
5170000
CY2022Q4 us-gaap Receivables Long Term Contracts Or Programs
ReceivablesLongTermContractsOrPrograms
17079000
CY2023Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
16652000
CY2022Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
37930000
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
22583000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
21922000
CY2023Q3 us-gaap Assets Current
AssetsCurrent
587670000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
548853000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
12413000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
14569000
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
9332000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
10678000
CY2023Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
26917000
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
28712000
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
18676000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
20224000
CY2023Q3 us-gaap Assets
Assets
655008000
CY2022Q4 us-gaap Assets
Assets
623036000
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
4472000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
11558000
CY2023Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
33735000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
31256000
CY2023Q3 bbio Accrued Research And Development Liabilities Current
AccruedResearchAndDevelopmentLiabilitiesCurrent
29244000
CY2022Q4 bbio Accrued Research And Development Liabilities Current
AccruedResearchAndDevelopmentLiabilitiesCurrent
39803000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4137000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3675000
CY2023Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
6592000
CY2022Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
8156000
CY2023Q3 bbio Accrued Professional And Other Accrued Liabilities Current
AccruedProfessionalAndOtherAccruedLiabilitiesCurrent
27885000
CY2022Q4 bbio Accrued Professional And Other Accrued Liabilities Current
AccruedProfessionalAndOtherAccruedLiabilitiesCurrent
26980000
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
106065000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
121428000
CY2023Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
441721000
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
430993000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
9812000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
12274000
CY2023Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
11785000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
26643000
CY2023Q3 us-gaap Liabilities
Liabilities
1848743000
CY2022Q4 us-gaap Liabilities
Liabilities
1867960000
CY2023Q3 bbio Temporary Equity Carrying Amount Net Including Portion Attributable To Noncontrolling Interests
TemporaryEquityCarryingAmountNetIncludingPortionAttributableToNoncontrollingInterests
1403000
CY2022Q4 bbio Temporary Equity Carrying Amount Net Including Portion Attributable To Noncontrolling Interests
TemporaryEquityCarryingAmountNetIncludingPortionAttributableToNoncontrollingInterests
-1589000
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
180323715
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
174131954
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
156817333
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
150625572
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
180000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
157000
CY2023Q3 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
6191761
CY2022Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
6191761
CY2023Q3 us-gaap Treasury Stock Value
TreasuryStockValue
275000000
CY2022Q4 us-gaap Treasury Stock Value
TreasuryStockValue
275000000
CY2023Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1459596000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
938703000
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
34000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-328000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2392353000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1918149000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-1207543000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-1254617000
CY2023Q3 us-gaap Minority Interest
MinorityInterest
12405000
CY2022Q4 us-gaap Minority Interest
MinorityInterest
11282000
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-1195138000
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-1243335000
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
655008000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
623036000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4091000
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
338000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
7558000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
75778000
CY2023Q3 us-gaap Cost Of Revenue
CostOfRevenue
598000
CY2022Q3 us-gaap Cost Of Revenue
CostOfRevenue
739000
us-gaap Cost Of Revenue
CostOfRevenue
1848000
us-gaap Cost Of Revenue
CostOfRevenue
2787000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
125136000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
92511000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
325485000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
308560000
CY2023Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
35777000
CY2022Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
31188000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
103007000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
111327000
CY2023Q3 us-gaap Restructuring Charges
RestructuringCharges
272000
CY2022Q3 us-gaap Restructuring Charges
RestructuringCharges
5016000
us-gaap Restructuring Charges
RestructuringCharges
7172000
us-gaap Restructuring Charges
RestructuringCharges
36074000
CY2023Q3 us-gaap Costs And Expenses
CostsAndExpenses
161783000
CY2022Q3 us-gaap Costs And Expenses
CostsAndExpenses
129454000
us-gaap Costs And Expenses
CostsAndExpenses
437512000
us-gaap Costs And Expenses
CostsAndExpenses
458748000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-157692000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-129116000
us-gaap Operating Income Loss
OperatingIncomeLoss
-429954000
us-gaap Operating Income Loss
OperatingIncomeLoss
-382970000
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
3793000
CY2022Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
2417000
us-gaap Investment Income Interest
InvestmentIncomeInterest
12460000
us-gaap Investment Income Interest
InvestmentIncomeInterest
3450000
CY2023Q3 us-gaap Interest Expense
InterestExpense
20306000
CY2022Q3 us-gaap Interest Expense
InterestExpense
19825000
us-gaap Interest Expense
InterestExpense
61021000
us-gaap Interest Expense
InterestExpense
60448000
CY2023Q3 bbio Gain From Sale Of Priority Review Voucher Net
GainFromSaleOfPriorityReviewVoucherNet
0
CY2022Q3 bbio Gain From Sale Of Priority Review Voucher Net
GainFromSaleOfPriorityReviewVoucherNet
0
bbio Gain From Sale Of Priority Review Voucher Net
GainFromSaleOfPriorityReviewVoucherNet
0
bbio Gain From Sale Of Priority Review Voucher Net
GainFromSaleOfPriorityReviewVoucherNet
107946000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-5283000
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
6331000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-4408000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-12060000
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-21796000
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-11077000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-52969000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
38888000
CY2023Q3 us-gaap Profit Loss
ProfitLoss
-179488000
CY2022Q3 us-gaap Profit Loss
ProfitLoss
-140193000
us-gaap Profit Loss
ProfitLoss
-482923000
us-gaap Profit Loss
ProfitLoss
-344082000
CY2023Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-2489000
CY2022Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-2854000
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-7869000
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-490000
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-176999000
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-137339000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-475054000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-343592000
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.08
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.08
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.93
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.93
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.99
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.99
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.34
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.34
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
163308632
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
163308632
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
147937817
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
147937817
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
158891152
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
158891152
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
146842453
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
146842453
CY2023Q3 us-gaap Profit Loss
ProfitLoss
-179488000
CY2022Q3 us-gaap Profit Loss
ProfitLoss
-140193000
us-gaap Profit Loss
ProfitLoss
-482923000
us-gaap Profit Loss
ProfitLoss
-344082000
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-29000
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
79000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
362000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-216000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-179517000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-140114000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-482561000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-344298000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-2489000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-2854000
us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-7869000
us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-490000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-177028000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-137260000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-474692000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-343808000
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-1243335000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
24330000
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
143016000
CY2023Q1 bbio Issuance Repurchase Of Noncontrolling Interest
IssuanceRepurchaseOfNoncontrollingInterest
42000
CY2023Q1 us-gaap Minority Interest Period Increase Decrease
MinorityInterestPeriodIncreaseDecrease
-1633000
CY2023Q1 us-gaap Noncontrolling Interest Decrease From Deconsolidation
NoncontrollingInterestDecreaseFromDeconsolidation
3950000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
316000
CY2023Q1 bbio Net Income Loss Excluding Redeemable Noncontrolling Interests Net Income Loss
NetIncomeLossExcludingRedeemableNoncontrollingInterestsNetIncomeLoss
-141585000
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-1213409000
CY2023Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
119000
CY2023Q2 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
1203000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
24614000
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1033000
CY2023Q2 bbio Issuance Repurchase Of Noncontrolling Interest
IssuanceRepurchaseOfNoncontrollingInterest
40000
CY2023Q2 us-gaap Minority Interest Period Increase Decrease
MinorityInterestPeriodIncreaseDecrease
-1918000
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
75000
CY2023Q2 bbio Net Income Loss Excluding Redeemable Noncontrolling Interests Net Income Loss
NetIncomeLossExcludingRedeemableNoncontrollingInterestsNetIncomeLoss
-159322000
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-1349971000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
24232000
CY2023Q3 bbio Issuance Repurchase Of Noncontrolling Interest
IssuanceRepurchaseOfNoncontrollingInterest
41000
CY2023Q3 us-gaap Minority Interest Period Increase Decrease
MinorityInterestPeriodIncreaseDecrease
-1148000
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-29000
CY2023Q3 bbio Net Income Loss Excluding Redeemable Noncontrolling Interests Net Income Loss
NetIncomeLossExcludingRedeemableNoncontrollingInterestsNetIncomeLoss
-177912000
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-1195138000
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-867002000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
25423000
CY2022Q1 bbio Issuance Repurchase Of Noncontrolling Interest
IssuanceRepurchaseOfNoncontrollingInterest
89000
CY2022Q1 us-gaap Minority Interest Period Increase Decrease
MinorityInterestPeriodIncreaseDecrease
48000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-251000
CY2022Q1 bbio Net Income Loss Excluding Redeemable Noncontrolling Interests Net Income Loss
NetIncomeLossExcludingRedeemableNoncontrollingInterestsNetIncomeLoss
-200290000
CY2022Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-1041023000
CY2022Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
56000
CY2022Q2 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
366000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
23901000
CY2022Q2 bbio Issuance Repurchase Of Noncontrolling Interest
IssuanceRepurchaseOfNoncontrollingInterest
4686000
CY2022Q2 us-gaap Minority Interest Period Increase Decrease
MinorityInterestPeriodIncreaseDecrease
-144000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-44000
CY2022Q2 bbio Net Income Loss Excluding Redeemable Noncontrolling Interests Net Income Loss
NetIncomeLossExcludingRedeemableNoncontrollingInterestsNetIncomeLoss
-580000
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-1013514000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
23231000
CY2022Q3 bbio Issuance Repurchase Of Noncontrolling Interest
IssuanceRepurchaseOfNoncontrollingInterest
77000
CY2022Q3 us-gaap Minority Interest Period Increase Decrease
MinorityInterestPeriodIncreaseDecrease
-65000
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
79000
CY2022Q3 bbio Net Income Loss Excluding Redeemable Noncontrolling Interests Net Income Loss
NetIncomeLossExcludingRedeemableNoncontrollingInterestsNetIncomeLoss
-139240000
CY2022Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-1127985000
us-gaap Profit Loss
ProfitLoss
-482923000
us-gaap Profit Loss
ProfitLoss
-344082000
us-gaap Share Based Compensation
ShareBasedCompensation
71685000
us-gaap Share Based Compensation
ShareBasedCompensation
69770000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
4909000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
5111000
bbio Noncash Lease Expense
NoncashLeaseExpense
3024000
bbio Noncash Lease Expense
NoncashLeaseExpense
4017000
bbio Accrual Of Payment In Kind Interest On Term Loan
AccrualOfPaymentInKindInterestOnTermLoan
6742000
bbio Accrual Of Payment In Kind Interest On Term Loan
AccrualOfPaymentInKindInterestOnTermLoan
0
bbio Gain Loss On Deconsolidation Of Entities
GainLossOnDeconsolidationOfEntities
-1241000
bbio Gain Loss On Deconsolidation Of Entities
GainLossOnDeconsolidationOfEntities
0
us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
-2951000
us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
-12969000
bbio Fair Value Of Shares Issued Under License Agreements
FairValueOfSharesIssuedUnderLicenseAgreements
0
bbio Fair Value Of Shares Issued Under License Agreements
FairValueOfSharesIssuedUnderLicenseAgreements
4567000
us-gaap Accretion Expense
AccretionExpense
6724000
us-gaap Accretion Expense
AccretionExpense
6469000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
52000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
1446000
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
0
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-6261000
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
12720000
bbio Gain From Sale Of Priority Review Voucher Excluding Transaction Costs
GainFromSaleOfPriorityReviewVoucherExcludingTransactionCosts
0
bbio Gain From Sale Of Priority Review Voucher Excluding Transaction Costs
GainFromSaleOfPriorityReviewVoucherExcludingTransactionCosts
110000000
bbio Gain From Recognition Of Receivable From Licensing And Collaboration Agreements
GainFromRecognitionOfReceivableFromLicensingAndCollaborationAgreements
0
bbio Gain From Recognition Of Receivable From Licensing And Collaboration Agreements
GainFromRecognitionOfReceivableFromLicensingAndCollaborationAgreements
12500000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
384000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-670000
bbio Increase Decrease Receivable From Licensing And Collaboration Agreements
IncreaseDecreaseReceivableFromLicensingAndCollaborationAgreements
-11909000
bbio Increase Decrease Receivable From Licensing And Collaboration Agreements
IncreaseDecreaseReceivableFromLicensingAndCollaborationAgreements
832000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
980000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-4072000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-1443000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-10095000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-3404000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1725000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-4156000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-9122000
bbio Increase Decrease In Accrued Research And Development Liabilities
IncreaseDecreaseInAccruedResearchAndDevelopmentLiabilities
-10544000
bbio Increase Decrease In Accrued Research And Development Liabilities
IncreaseDecreaseInAccruedResearchAndDevelopmentLiabilities
452000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-3671000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-4819000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-4464000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
16969000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-3055000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
1241000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-402901000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-326251000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
29726000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
134635000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
82550000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
452819000
us-gaap Payments To Acquire Equity Securities Fv Ni
PaymentsToAcquireEquitySecuritiesFvNi
78314000
us-gaap Payments To Acquire Equity Securities Fv Ni
PaymentsToAcquireEquitySecuritiesFvNi
26312000
us-gaap Proceeds From Sale Of Equity Securities Fv Ni
ProceedsFromSaleOfEquitySecuritiesFvNi
80963000
us-gaap Proceeds From Sale Of Equity Securities Fv Ni
ProceedsFromSaleOfEquitySecuritiesFvNi
28830000
bbio Decrease In Cash And Cash Equivalents Resulting From Deconsolidation Of Entities
DecreaseInCashAndCashEquivalentsResultingFromDeconsolidationOfEntities
503000
bbio Decrease In Cash And Cash Equivalents Resulting From Deconsolidation Of Entities
DecreaseInCashAndCashEquivalentsResultingFromDeconsolidationOfEntities
0
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
0
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
1500000
bbio Proceeds From Sale Of Priority Review Voucher
ProceedsFromSaleOfPriorityReviewVoucher
0
bbio Proceeds From Sale Of Priority Review Voucher
ProceedsFromSaleOfPriorityReviewVoucher
110000000
us-gaap Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
0
us-gaap Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
10000000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
871000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4020000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
54099000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
435182000
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
241250000
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
0
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
144049000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
bbio Proceeds From Issuance Of Common Stock Through At The Market Offering Net
ProceedsFromIssuanceOfCommonStockThroughAtTheMarketOfferingNet
64965000
bbio Proceeds From Issuance Of Common Stock Through At The Market Offering Net
ProceedsFromIssuanceOfCommonStockThroughAtTheMarketOfferingNet
0
bbio Financing Activity Transactions With Noncontrolling Interests
FinancingActivityTransactionsWithNoncontrollingInterests
1500000
bbio Financing Activity Transactions With Noncontrolling Interests
FinancingActivityTransactionsWithNoncontrollingInterests
0
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
0
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
20486000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
3397000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
2558000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
4325000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
1072000
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
0
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
1120000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
5222000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
609000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
456058000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-19511000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
107256000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
89420000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
416884000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
396365000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
524140000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
485785000
us-gaap Interest Paid Net
InterestPaidNet
50826000
us-gaap Interest Paid Net
InterestPaidNet
47575000
bbio Unpaid Issuance Cost On Private Placement Offering
UnpaidIssuanceCostOnPrivatePlacementOffering
455000
bbio Unpaid Issuance Cost On Private Placement Offering
UnpaidIssuanceCostOnPrivatePlacementOffering
0
bbio Payment In Kind Interest Added To Principal Of Term Loan
PaymentInKindInterestAddedToPrincipalOfTermLoan
0
bbio Payment In Kind Interest Added To Principal Of Term Loan
PaymentInKindInterestAddedToPrincipalOfTermLoan
8503000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
192000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
60000
bbio Noncash Or Part Noncash Investing Transfer From To Noncontrolling Interest
NoncashOrPartNoncashInvestingTransferFromToNoncontrollingInterest
-8313000
bbio Noncash Or Part Noncash Investing Transfer From To Noncontrolling Interest
NoncashOrPartNoncashInvestingTransferFromToNoncontrollingInterest
1153000
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
505213000
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
483235000
CY2023Q3 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
16652000
CY2022Q3 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
0
CY2023Q3 bbio Restricted Cash And Cash Equivalents Included In Prepaid Expenses And Other Current Assets
RestrictedCashAndCashEquivalentsIncludedInPrepaidExpensesAndOtherCurrentAssets
0
CY2022Q3 bbio Restricted Cash And Cash Equivalents Included In Prepaid Expenses And Other Current Assets
RestrictedCashAndCashEquivalentsIncludedInPrepaidExpensesAndOtherCurrentAssets
140000
CY2023Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
2275000
CY2022Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
2410000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
524140000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
485785000
us-gaap Nature Of Operations
NatureOfOperations
<div style="text-indent:0;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">1.</span><div id="organizationanddescription" style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Organization and De</span><span id="n1_organization_description_business"></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">scription of </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Business </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">BridgeBio Pharma, Inc. (“BridgeBio” or the “Company”) is a commercial-stage biopharmaceutical company founded to discover, create, test and deliver transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. BridgeBio’s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Since inception, BridgeBio has either created wholly-owned subsidiaries or has made investments in certain controlled entities, including partially-owned subsidiaries for which BridgeBio has a majority voting interest, and variable interest entities (“VIEs”) for which BridgeBio is the primary beneficiary (collectively, “we”, “our”, “us”). BridgeBio is headquartered in Palo Alto, California.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
bbio Cash Cash Equivalents And Restricted Cash Maturity Period
CashCashEquivalentsAndRestrictedCashMaturityPeriod
P90D
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
505213000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
376689000
CY2023Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
16652000
CY2022Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
37930000
CY2023Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2275000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2265000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
524140000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
416884000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and disclosure of contingent liabilities at the date of the condensed consolidated financial statements, and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions made in the accompanying condensed consolidated financial statements include, but are not limited to:</span></p><div style="margin-left:4.528%;text-indent:0;display:flex;margin-top:2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">•</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">accruals for research and development activities, such as clinical, development, regulatory, and sales-based milestone payments in our in-licensing agreements and asset acquisitions, </span></div></div><div style="margin-left:4.528%;text-indent:0;display:flex;margin-top:2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">•</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">accruals for performance-based milestone compensation arrangements, </span></div></div><div style="margin-left:4.528%;text-indent:0;display:flex;margin-top:2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">•</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">determining and allocating the transaction price to performance obligations for transactions accounted for under ASC 606, </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue from Contracts with Customers,</span></div></div><div style="margin-left:4.528%;text-indent:0;display:flex;margin-top:2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">•</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the expected recoverability and estimated useful lives of our long-lived assets, and</span></div></div><div style="margin-left:4.528%;text-indent:0;display:flex;margin-top:2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">•</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">additional charges as a result of, or that are associated with, any restructuring initiative as well as impairment and related charges.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We base our estimates on historical experience and on various other assumptions that we believe are reasonable. Actual results may differ from those estimates or assumptions.</span></p>
CY2023Q3 bbio Fair Value Assets Transfers Between Level One Level Two Or Level Three Amount
FairValueAssetsTransfersBetweenLevelOneLevelTwoOrLevelThreeAmount
0
CY2022Q4 bbio Fair Value Assets Transfers Between Level One Level Two Or Level Three Amount
FairValueAssetsTransfersBetweenLevelOneLevelTwoOrLevelThreeAmount
0
CY2023Q3 bbio Fair Value Liabilities Transfers Between Level One Level Two Or Level Three Amount
FairValueLiabilitiesTransfersBetweenLevelOneLevelTwoOrLevelThreeAmount
0
CY2022Q4 bbio Fair Value Liabilities Transfers Between Level One Level Two Or Level Three Amount
FairValueLiabilitiesTransfersBetweenLevelOneLevelTwoOrLevelThreeAmount
0
CY2023Q3 us-gaap Equity Securities Fv Ni Realized Gain Loss
EquitySecuritiesFvNiRealizedGainLoss
253000
CY2022Q3 us-gaap Equity Securities Fv Ni Realized Gain Loss
EquitySecuritiesFvNiRealizedGainLoss
1745000
us-gaap Equity Securities Fv Ni Realized Gain Loss
EquitySecuritiesFvNiRealizedGainLoss
9049000
us-gaap Equity Securities Fv Ni Realized Gain Loss
EquitySecuritiesFvNiRealizedGainLoss
360000
CY2023Q3 us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
-5603000
CY2022Q3 us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
8514000
us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
-12000000
us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
-13329000
CY2023Q3 bbio Net Gains Losses Included In Other Income Expense Net
NetGainsLossesIncludedInOtherIncomeExpenseNet
-5350000
CY2022Q3 bbio Net Gains Losses Included In Other Income Expense Net
NetGainsLossesIncludedInOtherIncomeExpenseNet
10259000
bbio Net Gains Losses Included In Other Income Expense Net
NetGainsLossesIncludedInOtherIncomeExpenseNet
-2951000
bbio Net Gains Losses Included In Other Income Expense Net
NetGainsLossesIncludedInOtherIncomeExpenseNet
-12969000
CY2023Q3 bbio Estimated Fair Value Of Outstanding Term Loan
EstimatedFairValueOfOutstandingTermLoan
385900000
CY2022Q4 bbio Estimated Fair Value Of Outstanding Term Loan
EstimatedFairValueOfOutstandingTermLoan
377200000
CY2023Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
464386000
CY2023Q3 bbio Cash Equivalents Unrealized Gains
CashEquivalentsUnrealizedGains
34000
CY2023Q3 bbio Cash Equivalents Unrealized Losses
CashEquivalentsUnrealizedLosses
0
CY2023Q3 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
464420000
CY2022Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
362062000
CY2022Q4 bbio Cash Equivalents Unrealized Gains
CashEquivalentsUnrealizedGains
0
CY2022Q4 bbio Cash Equivalents Unrealized Losses
CashEquivalentsUnrealizedLosses
-54000
CY2022Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
362008000
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
413916000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
328000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
413588000
CY2022 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2023Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
0
CY2022 bbio Short Term Marketable Securities Contractual Maturities
ShortTermMarketableSecuritiesContractualMaturities
P6M
CY2023Q3 bbio Adjustments Of Carrying Value Of Noncontrolling Interest Additional Paid In Capital
AdjustmentsOfCarryingValueOfNoncontrollingInterestAdditionalPaidInCapital
-2400000
bbio Adjustments Of Carrying Value Of Noncontrolling Interest Additional Paid In Capital
AdjustmentsOfCarryingValueOfNoncontrollingInterestAdditionalPaidInCapital
-8300000
CY2022Q3 bbio Adjustments Of Carrying Value Of Noncontrolling Interest Additional Paid In Capital
AdjustmentsOfCarryingValueOfNoncontrollingInterestAdditionalPaidInCapital
-300000
bbio Adjustments Of Carrying Value Of Noncontrolling Interest Additional Paid In Capital
AdjustmentsOfCarryingValueOfNoncontrollingInterestAdditionalPaidInCapital
1200000
CY2023Q3 us-gaap Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
500000
CY2022Q4 us-gaap Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
600000
us-gaap Acquired Finite Lived Intangible Assets Weighted Average Useful Life
AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
P11Y2M12D
CY2023Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
32500000
CY2022 us-gaap Acquired Finite Lived Intangible Assets Weighted Average Useful Life
AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
P12Y
CY2022Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
32500000
CY2023Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
5583000
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
3788000
CY2023Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
26917000
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
28712000
CY2023Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
600000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1800000
CY2022Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
600000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1800000
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
600000
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Next Rolling Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths
2400000
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Rolling Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo
2400000
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Rolling Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree
2400000
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Rolling Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour
2400000
CY2023Q3 bbio Finite Lived Intangible Assets Amortization Expense Rolling After Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFour
16700000
CY2023Q3 bbio Potential Milestone Fixed Monetary Amount Settlement In Cash
PotentialMilestoneFixedMonetaryAmountSettlementInCash
9506000
CY2023Q3 bbio Potential Milestone Accrued Amount Settlement In Cash
PotentialMilestoneAccruedAmountSettlementInCash
637000
CY2023Q3 bbio Potential Milestone Fixed Monetary Amount Settlement In Stock
PotentialMilestoneFixedMonetaryAmountSettlementInStock
51550000
CY2023Q3 bbio Potential Milestone Accrued Amount Settlement In Stock
PotentialMilestoneAccruedAmountSettlementInStock
8457000
CY2023Q3 bbio Potential Milestone Fixed Monetary Amount Settlement In Cash Or Stock At Sole Discretion
PotentialMilestoneFixedMonetaryAmountSettlementInCashOrStockAtSoleDiscretion
128483000
CY2023Q3 bbio Potential Milestone Accrued Amount Settlement In Cash Or Stock At Sole Discretion
PotentialMilestoneAccruedAmountSettlementInCashOrStockAtSoleDiscretion
1728000
CY2023Q3 bbio Potential Milestone Fixed Monetary Settlement Amount
PotentialMilestoneFixedMonetarySettlementAmount
189539000
CY2023Q3 bbio Potential Milestone Accrued Settlement Amount
PotentialMilestoneAccruedSettlementAmount
10822000
CY2023Q3 bbio Accrued Termination Charges
AccruedTerminationCharges
0
CY2023Q3 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
7643000
us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
22927000
CY2023Q3 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
920000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
2738000
CY2023Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
8563000
us-gaap Interest Expense Debt
InterestExpenseDebt
25665000
CY2022Q3 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
7643000
us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
22927000
CY2022Q3 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
895000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
2668000
CY2022Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
8538000
us-gaap Interest Expense Debt
InterestExpenseDebt
25595000
CY2023Q3 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0
CY2023Q3 bbio Children Intended For Treatement With Canavan Disease Maximum Age
ChildrenIntendedForTreatementWithCanavanDiseaseMaximumAge
P5Y
CY2023Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
1000000
CY2022Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
1128000
us-gaap Operating Lease Cost
OperatingLeaseCost
3024000
us-gaap Operating Lease Cost
OperatingLeaseCost
4017000
CY2023Q3 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
104000
CY2022Q3 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
110000
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
317000
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
334000
CY2023Q3 us-gaap Variable Lease Cost
VariableLeaseCost
1768000
CY2022Q3 us-gaap Variable Lease Cost
VariableLeaseCost
1567000
us-gaap Variable Lease Cost
VariableLeaseCost
5186000
us-gaap Variable Lease Cost
VariableLeaseCost
4632000
CY2023Q3 us-gaap Lease Cost
LeaseCost
2872000
CY2022Q3 us-gaap Lease Cost
LeaseCost
2805000
us-gaap Lease Cost
LeaseCost
8527000
us-gaap Lease Cost
LeaseCost
8983000
us-gaap Operating Lease Payments
OperatingLeasePayments
3671000
us-gaap Operating Lease Payments
OperatingLeasePayments
4819000
us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
325000
us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
317000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1179000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
240000
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y4M24D
CY2022Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y4M24D
CY2023Q3 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P2Y3M18D
CY2022Q3 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P3Y3M18D
CY2023Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0599
CY2022Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0576
CY2023Q3 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.0662
CY2022Q3 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.0662
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
960000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
4921000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
3937000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1868000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
849000
CY2023Q3 bbio Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
3361000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
15896000
CY2023Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
1947000
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
13949000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4137000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
9812000
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
13949000
CY2023Q3 us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
0
us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
0
CY2022Q3 us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
0
us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
0
CY2019Q4 bbio One Time Fees Receivable Noncurrent
OneTimeFeesReceivableNoncurrent
10000000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
27230000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
77883000
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
18658000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
71244000
CY2023Q3 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2022Q3 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
67000
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
12720000
CY2023Q3 us-gaap Severance Costs1
SeveranceCosts1
0
CY2022Q3 us-gaap Severance Costs1
SeveranceCosts1
997000
us-gaap Severance Costs1
SeveranceCosts1
715000
us-gaap Severance Costs1
SeveranceCosts1
10409000
CY2023Q3 us-gaap Business Exit Costs1
BusinessExitCosts1
272000
CY2022Q3 us-gaap Business Exit Costs1
BusinessExitCosts1
3952000
us-gaap Business Exit Costs1
BusinessExitCosts1
6457000
us-gaap Business Exit Costs1
BusinessExitCosts1
12945000
CY2023Q3 us-gaap Restructuring Settlement And Impairment Provisions
RestructuringSettlementAndImpairmentProvisions
272000
CY2022Q3 us-gaap Restructuring Settlement And Impairment Provisions
RestructuringSettlementAndImpairmentProvisions
5016000
us-gaap Restructuring Settlement And Impairment Provisions
RestructuringSettlementAndImpairmentProvisions
7172000
us-gaap Restructuring Settlement And Impairment Provisions
RestructuringSettlementAndImpairmentProvisions
36074000
CY2022Q4 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
6826000
CY2021Q4 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
0
bbio Reclassification Of Final Payment Obligation Related To Manufacturing Agreement Recognized In Prior Period
ReclassificationOfFinalPaymentObligationRelatedToManufacturingAgreementRecognizedInPriorPeriod
0
bbio Reclassification Of Final Payment Obligation Related To Manufacturing Agreement Recognized In Prior Period
ReclassificationOfFinalPaymentObligationRelatedToManufacturingAgreementRecognizedInPriorPeriod
2185000
us-gaap Restructuring Settlement And Impairment Provisions
RestructuringSettlementAndImpairmentProvisions
7172000
us-gaap Restructuring Settlement And Impairment Provisions
RestructuringSettlementAndImpairmentProvisions
36074000
us-gaap Payments For Restructuring
PaymentsForRestructuring
13851000
us-gaap Payments For Restructuring
PaymentsForRestructuring
17616000
us-gaap Restructuring Reserve Settled Without Cash2
RestructuringReserveSettledWithoutCash2
0
us-gaap Restructuring Reserve Settled Without Cash2
RestructuringReserveSettledWithoutCash2
13892000
CY2023Q3 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
147000
CY2022Q3 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
6751000
CY2023Q3 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
147000
CY2022Q4 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
6826000
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022Q3 bbio Percentage Of Corporate Alternative Minimum Tax Rate
PercentageOfCorporateAlternativeMinimumTaxRate
0.15
CY2022Q3 bbio Percentage Of Excise Tax Benefit On Corporate Stock Buy Back
PercentageOfExciseTaxBenefitOnCorporateStockBuyBack
0.01
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
49002490
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
55789481

Files In Submission

Name View Source Status
0000950170-23-058255-index-headers.html Edgar Link pending
0000950170-23-058255-index.html Edgar Link pending
0000950170-23-058255.txt Edgar Link pending
0000950170-23-058255-xbrl.zip Edgar Link pending
bbio-20230930.htm Edgar Link pending
bbio-20230930.xsd Edgar Link pending
bbio-ex10_1.htm Edgar Link pending
bbio-ex31_1.htm Edgar Link pending
bbio-ex31_2.htm Edgar Link pending
bbio-ex32_1.htm Edgar Link pending
bbio-ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
bbio-20230930_cal.xml Edgar Link unprocessable
bbio-20230930_def.xml Edgar Link unprocessable
bbio-20230930_pre.xml Edgar Link unprocessable
bbio-20230930_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
bbio-20230930_htm.xml Edgar Link completed
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending